TransCode Therapeutics, Inc. (RNAZ)
RNAZ Stock Price Chart
Explore TransCode Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze RNAZ price movements and trends.
RNAZ Company Profile
Discover essential business fundamentals and corporate details for TransCode Therapeutics, Inc. (RNAZ) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
8 Jul 2021
Employees
12.00
CEO
Philippe Calais
Description
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
RNAZ Financial Timeline
Browse a chronological timeline of TransCode Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 18 Aug 2026
Earnings released on 15 May 2026
EPS came in at -$21.28 .
Earnings released on 15 Apr 2026
EPS came in at -$16.42 falling short of the estimated -$10.08 by -62.90%.
Earnings released on 14 Nov 2025
EPS came in at -$5.49 surpassing the estimated -$9.24 by +40.58%.
Earnings released on 14 Aug 2025
EPS came in at -$4.94 surpassing the estimated -$8.68 by +43.09%.
Stock split effective on 15 May 2025
Shares were split 1 : 28 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 May 2025
EPS came in at -$16.81 falling short of the estimated -$3.21 by -423.68%.
Earnings released on 28 Mar 2025
EPS came in at -$16.61 surpassing the estimated -$105.93 by +84.32%.
Stock split effective on 4 Dec 2024
Shares were split 1 : 33 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$5.28 surpassing the estimated -$16.17 by +67.35%.
Earnings released on 14 Aug 2024
EPS came in at -$24.42 falling short of the estimated -$19.14 by -27.59%.
Earnings released on 15 May 2024
EPS came in at -$21.45 surpassing the estimated -$23.10 by +7.14%.
Earnings released on 29 Mar 2024
EPS came in at -$99.99 falling short of the estimated -$10.80 by -825.83%, while revenue for the quarter reached $753.15k .
Stock split effective on 16 Jan 2024
Shares were split 1 : 40 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2023
EPS came in at -$2.22k falling short of the estimated -$1.98k by -12.00%.
Earnings released on 14 Aug 2023
EPS came in at -$4.34k surpassing the estimated -$4.48k by +2.95%.
Stock split effective on 23 May 2023
Shares were split 1 : 20 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 31 Mar 2023
EPS came in at -$10.30k falling short of the estimated -$10.03k by -2.63%.
Earnings released on 30 Mar 2023
EPS came in at -$0.23 surpassing the estimated -$0.38 by +39.47%.
Earnings released on 14 Nov 2022
EPS came in at -$8.71k surpassing the estimated -$10.56k by +17.50%.
Earnings released on 15 Aug 2022
EPS came in at -$9.50k falling short of the estimated -$0.30 by -3.17m%.
Earnings released on 16 May 2022
EPS came in at -$7.13k .
Earnings released on 31 Mar 2022
EPS came in at -$6.07k falling short of the estimated -$200.00 by -2.94k%.
Earnings released on 15 Nov 2021
EPS came in at -$5.28k .
Earnings released on 23 Aug 2021
EPS came in at $589.73 .
RNAZ Stock Performance
Access detailed RNAZ performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
